Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited, a leader in cancer and inflammation research, has secured a $1.8 million loan from Endpoints Capital, underpinned by an expected $2.3 million R&D tax rebate from the Australian Government. The loan, which carries an interest rate of 15.80%, is aimed at bolstering the company’s financial position ahead of receiving the rebate for the 2023-24 financial year. Noxopharm specializes in developing novel treatments and owns a major stake in Nyrada Inc, focusing on small molecule therapies.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.
